Press Releases
Information for the media and for our investors
Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
Formycon AG today published its audited consolidated financial statements for the 2025 financial year and provided a forecast for the 2026 financial year.
April 22, 2026
Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
Formycon AG plans to publish its results of the financial year 2025 on April 22, 2026. The conference call, which will be broadcast live on the internet, will take place on Wednesday, April 22, 2026, at 3:00 PM (CEST) in English.
April 20, 2026
Formycon AG announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements
Formycon AG announces that, as part of the final preparation of the annual financial statements for the 2025 fiscal year, changes have occurred in the key performance indicators Group EBITDA and Group adjusted EBITDA, as well as in working capital, compared to the preliminary figures published on March 4, 2026.
April 15, 2026
Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
Formycon AG and its license partner Klinge Biopharma GmbH announce a settlement and license agreement with Regeneron Pharmaceuticals, Inc. and Bayer Healthcare LLC, resolving all patent disputes related to the EU-approved Eylea® 2 mg biosimilars AHZANTIVE® and Baiama®
March 19, 2026
Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Formycon AG announces that the publication of the audited 2025 annual and consolidated financial statements, originally scheduled for March 26, 2026, will be postponed.
March 18, 2026
Formycon AG publishes preliminary figures for the 2025 fiscal year
Strong increase in Group revenues in the fourth quarter, but full-year revenues still expected to remain below guidance - Group EBITDA expected to be at the upper end of the expected range - Adjusted EBITDA as well as working capital expected to be improved versus guidance
March 4, 2026
Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
Formycon AG announces that the pivotal Dahlia pharmacokinetic study (PK study) has successfully met its primary study objective.
February 25, 2026
Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
Formycon AG and Lotus Pharmaceutical today announced the conclusion of an exclusive license agreement for Formycon’s Keytruda® biosimilar candidate FYB206 (Pembrolizumab).
February 11, 2026
